Myocarditis after vaccination, firm data
February 12, 2022
2,195,824
64,300
18,837
3.79%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Dr John Campbell Episodes Around February 12, 2022
See what was published immediately before and after this episode.
30:12Now PlayingMyocarditis after vaccination, firm data
YouTube Description
as posted by the channelJohn, please could you review this article from Israel national News, it says the risk of myocarditis following mRNA COVID vaccination is around 133 times greater than the background risk in the population, is this true? If it is true, why is this not all over MSM?
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 (25 January)
JAMA. 2022;327(4):331-340. doi:10.1001/jama.2021.24110
Importance
Vaccination against COVID-19 provides clear public health benefits,
but vaccination also carries potential risks.
The risks and outcomes of myocarditis after COVID-19 vaccination are unclear.
To describe reports of myocarditis and the reporting rates after mRNA-based COVID-19 vaccination in the US.
Descriptive study
Reports of myocarditis to the Vaccine Adverse Event Reporting System (VAERS)
After mRNA-based COVID-19 vaccine administration
Between December 2020 and August 2021 in
n = 192,405,448 older than 12 years of age in the US
During the analytic period
BNT162b2 vaccine, 12 years and older
mRNA-1273 vaccine, 18 years and over
Exposures
Vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)
Main Outcomes and Measures
Expected rates of myocarditis by age and sex were calculated using 2017-2019 claims data.
For persons younger than 30 years of age, medical record reviews and clinician interviews were conducted to describe clinical presentation, diagnostic test results, treatment, and early outcomes.
Results
Among 192,405,448 persons
Receiving a total of 354,100, 845 mRNA vaccines
1,991 reports of myocarditis to VAERS
1,626 met the case definition of myocarditis
Of those with myocarditis
Median age, 21 years (IQR, 16-31 years)
Median time to symptom onset, 2 days (IQR, 1-3 days)
Males
Comprised 82% of myocarditis cases
Reporting rates for cases of myocarditis
Within 7 days after COVID-19 vaccination,
exceeded the expected rates of myocarditis across multiple age and sex strata
Rates of myocarditis were highest after the second vaccination dose
Adolescent males aged 12 to 15 years
70.7 per million doses of the BNT162b2 vaccine
(One case per 14,144 vaccinations)
Males aged 16 to 17 years
105.9 per million doses of the BNT162b2 vaccine
(One case per 9,442 vaccinations)
Males aged 18 to 24 years
52.4 per million doses of the BNT162b2 vaccine
(One case per 19,083 vaccinations)
56.3 per million doses of the mRNA-1273 vaccine
(One case per 17,761 vaccinations)
Myocarditis in the under 30s
826 cases of myocarditis, who had detailed clinical information available
Of these 826 cases of myocarditis
792 of 809 (98%) had elevated troponin levels
569 of 794 (72%) had abnormal electrocardiogram results
223 of 312 (72%) had abnormal cardiac magnetic resonance imaging results
Hospital data
784 of 813 (96%) were hospitalized
577 of 661 (87%) had resolution of presenting symptoms by hospital discharge
Most common treatment
Nonsteroidal anti-inflammatory drugs 589 of 676 (87%).
7.26 + 105.86 = 113.12
Expected, 1.34
113.12
= 84.4
1.34
Supplement
CDC’s case definition of probable myocarditis
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.